New Managing Director of Europe
BioTek Instruments welcomes Dr Dirk Frese to the company as managing director, Europe.
BioTek Instruments welcomes Dr Dirk Frese to the company as managing director, Europe. The company reports that in this new position, Dr Frese will be responsible for business integration and advancement within Europe.
Peter Weith, the company’s vice president of marketing, says, “Dr Frese has a unique set of skills, creating cutting-edge business development programmes, within Europe and globally, for a recognized market leader. In addition, his strong academic background will resonate with our research-based products.”
Before joining the company, Dr Frese was director and global category manager for analytical technologies at Thermo Fisher Scientific. He has also worked at Fisher Scientific,and held several management positions at Merck Eurolab and Ciba-Geigy.
For more information visit www.biotek.com
An LC–HRMS Method for Separation and Identification of Hemoglobin Variant Subunits
March 6th 2025Researchers from Stanford University’s School of Medicine and Stanford Health Care report the development of a liquid chromatography high-resolution mass spectrometry (LC–HRMS) method for identifying hemoglobin (Hb) variants. The method can effectively separate several pairs of normal and variant Hb subunits with mass shifts of less than 1 Da and accurately identify them in intact-protein and top-down analyses.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
